Related Experiment Video
Updated: Aug 11, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
[Use of digitalis in chronic heart failure: an unresolved problem?]
Summary
The DIG trial found digoxin did not affect mortality in heart failure patients but significantly reduced hospitalizations. This highlights ongoing debates about digitalis use and patient selection in heart failure treatment.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- The role of digitalis (specifically digoxin) in heart failure management remains a subject of debate.
- The Digitalis Investigation Group (DIG) trial aimed to clarify the efficacy and safety of digoxin in a large patient cohort.
Discussion:
- The DIG trial revealed a neutral effect on mortality but a significant reduction in hospitalizations for worsening heart failure among patients receiving digoxin.
- Concerns were raised regarding patient selection criteria, potentially high digoxin dosages, and the precise attribution of benefits.
- The study's data limitations preclude definitive conclusions on beta-blocker use or the combined effects of digitalis and beta-blockers.
Key Insights:
- Digoxin therapy in heart failure patients, as per the DIG trial, does not increase mortality.
- A significant decrease in heart failure-related hospitalizations was observed in the digoxin group.
- The trial underscored the need for careful patient selection and dosage optimization for digoxin therapy.
Outlook:
- Further research is warranted to refine patient selection criteria for digoxin therapy.
- Investigating the synergistic or antagonistic effects of digoxin with other heart failure medications, like beta-blockers, is crucial.
- Optimizing digoxin dosage strategies may enhance its therapeutic benefits while minimizing potential risks.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...